Key Drivers
- Strong cash conversion
- Solid balance sheet
- Rising working capital
AIAI Summary
PGNY now looks less like a pure growth story and more like a cash-generative healthcare platform with upside optionality: it is still delivering double-digit organic growth and strong free cash flow after a major client loss, but the key watchout is whether it can sustain that growth while managing churn, working-capital pressure, and margin-rebuilding execution.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong cash conversion
- •Solid balance sheet
- •Rising working capital
PGNY looks fundamentally strong with profitable growth, solid cash generation, and a healthy balance sheet, but rising working-capital demands and a still-premium valuation mean upside depends on continued execution rather than obvious cheapness.
Price Behavior
Key Price Behavior Insights:
- •Higher highs
- •Resistance breakout
- •Stretched advance
Over the last month, PGNY has built a strong uptrend by holding above $28.50 and printing a new high near $30.20, but the move is now extended/overbought so near-term risk-reward is less attractive.
Fast steady climb from the mid-$20s to a new short-term high suggests short-term pullback risk
Sentiment & News
Key News Insights:
- •Price strength
- •Below value
- •CFO sale
Progyny (PGNY) rose 3.8% while still trading below its GF Value estimate, and the CFO's recent share sale adds a notable insider-activity signal to the stock's mid-June momentum.
The news is mildly positive for momentum but tempered by valuation and insider-selling concerns
Similar Companies in Healthcare
Other companies in the same sector with AI ratings